NCT07329322 is a Phase 2 clinical trial of Sacituzumab Tirumotecan in Non-Small Cell Lung Cancer, sponsored by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd..

Who is sponsoring NCT07329322?

NCT07329322 is sponsored by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd..

What drugs are being tested in NCT07329322?

Interventions in NCT07329322: Sacituzumab Tirumotecan, Osimertinib.

What condition does NCT07329322 study?

NCT07329322 studies Non-Small Cell Lung Cancer.

Is NCT07329322 still recruiting?

NCT07329322 is currently not yet recruiting. Last updated 9 January 2026.

Last reviewed 2026-01-09 · How we verify

NCT07329322

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib or Sacituzumab Tirumotecan for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

Not yet recruiting Phase 2 Last updated 9 January 2026

What this trial tests

Phase 2 trial testing Sacituzumab Tirumotecan in Non-Small Cell Lung Cancer in 60 participants. Not yet recruiting.

Timeline

1 February 2026

Primary endpoint
31 August 2027

31 October 2032

Quick facts

Lead sponsor	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase	Phase 2
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	60
Start date	1 February 2026
Primary completion	31 August 2027
Estimated completion	31 October 2032

Drugs / interventions tested

Sacituzumab Tirumotecan — full drug profile →
Osimertinib (osimertinib) — full drug profile →

Conditions studied

Non-Small Cell Lung Cancer — all drugs for Non-Small Cell Lung Cancer →

Sponsor

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. — full company profile →

Who can join

Adults 18 to 75, any sex, with Non-Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the study to evaluate the safety and efficacy of Sacituzumab Tirumotecan in combination with osimertinib or as monotherapy for neoadjuvant treatment in patients with resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Sacituzumab Tirumotecan

Trials testing the same drug.

NCT07511023 — Phase 2 Trial Of Sacituzumab Tirumotecan For Treatment Of Refractory Metastatic Or Unresectable Squamous Cell Carcinoma · Phase 2 · not yet recruiting
NCT07388875 — Sacituzumab Tirumotecan Plus Anlotinib in Previously Treated ES-SCLC · Phase 2 · not yet recruiting
NCT07216703 — A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintena · Phase 3 · recruiting
NCT07193160 — Sacituzumab Tirumotecan in Combination With Furmonertinib as Second-line Treatment for EGFR-mutant Advanced or Metastati · Phase 2 · not yet recruiting
NCT07179783 — Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) a · Phase 2 · recruiting

Other recruiting trials for Non-Small Cell Lung Cancer

Currently open trials in the same condition.

NCT07140315 — DK222 Study at Hopkins · Phase 1 · recruiting
NCT07487883 — Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors · recruiting
NCT07413757 — CHOICE:Decision Factor of EGFR-TKI in Chinese IV NSCLC · recruiting
NCT07460999 — Singing Training vs Usual Care 6-18 Months After Surgical Resection for Non-small Cell Lung Cancer (NSCLC) · NA · recruiting
NCT07479277 — Progel Platinum for Air Leak Reduction After VATS Lobectomy for NSCLC · NA · recruiting

Other Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. trials

Trials by the same sponsor.

NCT07459998 — SKB103 for Injection in Advanced Solid Tumors · Phase 1, PHASE2 · not yet recruiting
NCT07380386 — SKB105 for Injection in Advanced Solid Tumors · Phase 1, PHASE2 · not yet recruiting
NCT07488065 — A Study of SKB575 (HBM7575) Injection in Healthy Participants and Atopic Dermatitis Participants · Phase 1 · recruiting
NCT07308106 — A Phase II Clinical Study of SKB571 as Monotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung C · Phase 2 · not yet recruiting
NCT07296809 — SKB500 Combinations in Patients With Small Cell Lung Cancer · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07329322 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Last refreshed: 9 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07329322.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing